Capital Fund Management (CFM)
PTGX icon

Capital Fund Management (CFM)’s Protagonist Therapeutics PTGX Stock Holding History

Capital Fund Management (CFM)’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-20,348
Closed -$1.35M – 2600
2025
Q3 		$1.35M Sell
20,348
-29,457
-59% -$1.67M ﹤0.01% 1959
2025
Q2 		$2.75M Buy
+49,805
New +$2.39M 0.01% 1508
2025
Q1 		– Sell
-28,058
Closed -$1.08M – 2286
2024
Q4 		$1.08M Buy
+28,058
New +$1.22M ﹤0.01% 1730
2023
Q4 		– Sell
-12,629
Closed -$211K – 2265
2023
Q3 		$211K Sell
12,629
-13,976
-53% -$271K ﹤0.01% 1899
2023
Q2 		$735K Buy
+26,605
New +$666K ﹤0.01% 1492
2022
Q3 		– Sell
-116,807
Closed -$924K – 1602
2022
Q2 		$924K Buy
+116,807
New +$1.41M 0.01% 1100

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Capital Fund Management (CFM)'s PTGX Position: Q4 2025 in Review

Capital Fund Management (CFM) sold out of Protagonist Therapeutics (PTGX) in Q4 2025, closing a stake of 20,348 shares — an estimated $1.35M sold.

Capital Fund Management (CFM) first reported a position in PTGX in Q2 2022 and held it in 6 quarters. The position peaked at $2.75M in Q2 2025. 316 funds tracked by Wall St. Rank hold PTGX as of Q4 2025.

  • Capital Fund Management (CFM) reported no remaining Protagonist Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Capital Fund Management (CFM) sold 20,348 Protagonist Therapeutics shares in Q4 2025, an estimated $1.35M.
  • Capital Fund Management (CFM) first reported a position in Protagonist Therapeutics in Q2 2022 and held it in 6 quarters.
  • Capital Fund Management (CFM)'s Protagonist Therapeutics position peaked at $2.75M in Q2 2025.
  • 316 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q4 2025.

Based on Capital Fund Management (CFM)'s 13F filing for Q4 2025, filed 17 Feb 2026.